Ask
Search
My library
ORKG

ORKG Ask

Our mission is to organize scholarly knowledge and make it accessible to humans and machines.

About

About ORKG Ask
Report issue
Statistics
Contact

Legal

Terms of use
Data protection (sheet)
Imprint
Accessibility
License

Technical

We
open source
System status
Changelog
Frontend: v1.41.0
Backend: v1.13.4

We use cookies to provide a better user experience.

Data Protection

Factors Associated with Access to Immunotherapy and Its Impact on Survival in Mucosal Melanoma

Lee, Joanne Jee Yeon
Kearns, Donovan
Rodrigues, Medora
Babcock, Blake
Solomon, Naveenraj L, MD
Senthil, Maheswari, MD
Reeves, Mark E, MD, PhD
Garberoglio, Carlos A, MD
Namm, Jukes P, MD

Publication date

December 2018

Publisher

TheScholarsRepository@LLU: Digital Archive of Research, Scholarship & Creative Works

Language

English

Abstract

Mucosal melanoma is rare, comprising only 1.4% of all melanomas in the United States. Yet it is associated with a worse prognosis compared to cutaneous melanoma due to aggressive biology and advanced stage at diagnosis with a reported 5-year survival rate of less than 30%. Although there are no established guidelines for the treatment of mucosal melanoma, immunotherapy has been increasingly used for the management of advanced mucosal melanoma

Extracted data

Related items

J Am Acad Dermatol

Background:Mucosal melanomas are rare and aggressive neoplasms, with little published population-bas...

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions

Ralli M.
Botticelli A.
Visconti I. C.
Angeletti D.
Fiore M.
Marchetti P.
Lambiase A.
De Vincentiis M.
Greco A.

January 2020

Melanoma is one of the most immunologic malignancies based on its higher prevalence in immune-compro...

Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma

December 2018

International audienceBackground: The objective was to assess the response rate and survival of pati...

Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based study

van Zeijl, Michiel C T
Boer, Florine L
van Poelgeest, Mariëtte I E
van den Eertwegh, Alfons J M
Wouters, Michel W J M
de Wreede, Liesbeth C
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan Willem B
Hospers, Geke A P
Piersma, Djura
van Rijn, Rozemarijn S
Suijkerbuijk, Karijn P M
Ten Tije, Albert J
van der Veldt, Astrid A M
Vreugdenhil, Gerard
Boers-Sonderen, Marye J
Kapiteijn, Ellen H W
Haanen, John B A G

September 2020

BACKGROUND: Mucosal melanoma (MM) is rare and has a poor prognosis. Since 2011, new effective treatm...

Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands – A nationwide population-based study

van Zeijl, Michiel C.T.
Boer, Florine L.
van Poelgeest, Mariëtte I.E.
van den Eertwegh, Alfons J.M.
Wouters, Michel W.J.M.
de Wreede, Liesbeth C.
Aarts, Maureen J.B.
van den Berkmortel, Franchette W.P.J.
de Groot, Jan Willem B.
Hospers, Geke A.P.
Piersma, Djura
van Rijn, Rozemarijn S.
Suijkerbuijk, Karijn P.M.
ten Tije, Albert J.
van der Veldt, Astrid A.M.
Vreugdenhil, Gerard
Boers-Sonderen, Marye J.
Kapiteijn, Ellen H.W.
Haanen, John B.A.G.

September 2020

Background: Mucosal melanoma (MM) is rare and has a poor prognosis. Since 2011, new effective treatm...

Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands: a nationwide population-based study

Zeijl, M.C.T. van
Boer, F.L.
Poelgeest, M.I.E. van
Eertwegh, A.J.M. van den
Wouters, M.W.J.M.
Wreede, L.C. de
Aarts, M.J.B.
Berkmortel, F.W.P.J. van den
Groot, J.W.B. de
Hospers, G.A.P.
Piersma, D.
Rijn, R.S. van
Suijkerbuijk, K.P.M.
Tije, A.J. ten
Veldt, A.A.M. van der
Vreugdenhil, G.
Boers-Sonderen, M.J.
Kapiteijn, E.H.W.
Haanen, J.B.A.G.

September 2020

Background: Mucosal melanoma (MM) is rare and has a poor prognosis. Since 2011, new effective treatm...

Disparity in outcomes of melanoma adjuvant immunotherapy by demographic profile

Ikeguchi, Alexandra
Machiorlatti, Michael
Vesely, Sara K.

July 2020

Background: Randomized comparisons have demonstrated survival benefit of adjuvant immunotherapy in n...

J Am Acad Dermatol

Background:Mucosal melanomas are rare and aggressive neoplasms, with little published population-bas...

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions

Ralli M.
Botticelli A.
Visconti I. C.
Angeletti D.
Fiore M.
Marchetti P.
Lambiase A.
De Vincentiis M.
Greco A.

January 2020

Melanoma is one of the most immunologic malignancies based on its higher prevalence in immune-compro...

Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma

December 2018

International audienceBackground: The objective was to assess the response rate and survival of pati...

Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based study

van Zeijl, Michiel C T
Boer, Florine L
van Poelgeest, Mariëtte I E
van den Eertwegh, Alfons J M
Wouters, Michel W J M
de Wreede, Liesbeth C
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan Willem B
Hospers, Geke A P
Piersma, Djura
van Rijn, Rozemarijn S
Suijkerbuijk, Karijn P M
Ten Tije, Albert J
van der Veldt, Astrid A M
Vreugdenhil, Gerard
Boers-Sonderen, Marye J
Kapiteijn, Ellen H W
Haanen, John B A G

September 2020

BACKGROUND: Mucosal melanoma (MM) is rare and has a poor prognosis. Since 2011, new effective treatm...

Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands – A nationwide population-based study

van Zeijl, Michiel C.T.
Boer, Florine L.
van Poelgeest, Mariëtte I.E.
van den Eertwegh, Alfons J.M.
Wouters, Michel W.J.M.
de Wreede, Liesbeth C.
Aarts, Maureen J.B.
van den Berkmortel, Franchette W.P.J.
de Groot, Jan Willem B.
Hospers, Geke A.P.
Piersma, Djura
van Rijn, Rozemarijn S.
Suijkerbuijk, Karijn P.M.
ten Tije, Albert J.
van der Veldt, Astrid A.M.
Vreugdenhil, Gerard
Boers-Sonderen, Marye J.
Kapiteijn, Ellen H.W.
Haanen, John B.A.G.

September 2020

Background: Mucosal melanoma (MM) is rare and has a poor prognosis. Since 2011, new effective treatm...

Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands: a nationwide population-based study

Zeijl, M.C.T. van
Boer, F.L.
Poelgeest, M.I.E. van
Eertwegh, A.J.M. van den
Wouters, M.W.J.M.
Wreede, L.C. de
Aarts, M.J.B.
Berkmortel, F.W.P.J. van den
Groot, J.W.B. de
Hospers, G.A.P.
Piersma, D.
Rijn, R.S. van
Suijkerbuijk, K.P.M.
Tije, A.J. ten
Veldt, A.A.M. van der
Vreugdenhil, G.
Boers-Sonderen, M.J.
Kapiteijn, E.H.W.
Haanen, J.B.A.G.

September 2020

Background: Mucosal melanoma (MM) is rare and has a poor prognosis. Since 2011, new effective treatm...

Disparity in outcomes of melanoma adjuvant immunotherapy by demographic profile

Ikeguchi, Alexandra
Machiorlatti, Michael
Vesely, Sara K.

July 2020

Background: Randomized comparisons have demonstrated survival benefit of adjuvant immunotherapy in n...

J Am Acad Dermatol

Background:Mucosal melanomas are rare and aggressive neoplasms, with little published population-bas...

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions

Ralli M.
Botticelli A.
Visconti I. C.
Angeletti D.
Fiore M.
Marchetti P.
Lambiase A.
De Vincentiis M.
Greco A.

January 2020

Melanoma is one of the most immunologic malignancies based on its higher prevalence in immune-compro...

Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma

December 2018

International audienceBackground: The objective was to assess the response rate and survival of pati...